flow semaglutide FLOW: Scores Big in Diabetic Patients With CKD Media Centre | EASD

After propensity score matching the GLP-1 cohort (n=45,704) included 35,753 (78.2%) women and 7,852 (17.2%) men with a mean age of 61.1, while the OWLD cohort (n=45,704) included 35,732 (78.2%) women and 7,815 (17.1%) men with a mean age of 61.0

Beyond weight loss, key health indicators, such as blood pressure and glucose levels, often exhibit favorable changes, heightening the treatments comprehensive wellness approach

Moreover, the degree and trajectory of weight loss may have differed substantially between semaglutide users and controls, particularly if weight loss in the control group was achieved through lifestyle-related approaches rather than pharmacologic treatment, but these differences could not be measured within TriNetX

This matters with GLP-1 treatment because dosing, nausea management, hydration, protein intake, and long-term planning all affect the experience